| pubmed-article:20306568 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20306568 | lifeskim:mentions | umls-concept:C0019163 | lld:lifeskim |
| pubmed-article:20306568 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:20306568 | lifeskim:mentions | umls-concept:C0003873 | lld:lifeskim |
| pubmed-article:20306568 | lifeskim:mentions | umls-concept:C0524909 | lld:lifeskim |
| pubmed-article:20306568 | lifeskim:mentions | umls-concept:C1122087 | lld:lifeskim |
| pubmed-article:20306568 | lifeskim:mentions | umls-concept:C2709058 | lld:lifeskim |
| pubmed-article:20306568 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:20306568 | pubmed:dateCreated | 2010-3-19 | lld:pubmed |
| pubmed-article:20306568 | pubmed:abstractText | We report a case of reactivation of hepatitis B virus (HBV) infection with subacute liver failure during administration of adalimumab, followed by a literature review of all 19 published cases, with a focus on the effect of antiviral prophylaxis. Eight patients were given prophylaxis and had a good outcome. Of the 11 patients without prophylaxis, six patients developed a reactivation and needed to stop anti-TNFalpha therapy (P = 0.017). One patient developed an acute liver failure, necessitating urgent liver transplantation. One patient died. Administration of anti-TNFalpha therapy can lead to HBV reactivation, with a possible lethal outcome. High-risk patients and possibly all patients should be screened for hepatitis B surface antigen and anti-HBV core antibody before starting anti-TNFalpha therapy. Administration of antiviral prophylaxis proves beneficial in prevention of reactivation in hepatitis B surface antigen positive patients. | lld:pubmed |
| pubmed-article:20306568 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20306568 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20306568 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20306568 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20306568 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20306568 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20306568 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20306568 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20306568 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20306568 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:20306568 | pubmed:issn | 1473-5687 | lld:pubmed |
| pubmed-article:20306568 | pubmed:author | pubmed-author:De... | lld:pubmed |
| pubmed-article:20306568 | pubmed:author | pubmed-author:ColleIsabelle... | lld:pubmed |
| pubmed-article:20306568 | pubmed:author | pubmed-author:Van... | lld:pubmed |
| pubmed-article:20306568 | pubmed:author | pubmed-author:OrlentHansH | lld:pubmed |
| pubmed-article:20306568 | pubmed:author | pubmed-author:GeertsAnjaA | lld:pubmed |
| pubmed-article:20306568 | pubmed:author | pubmed-author:VerhelstXavie... | lld:pubmed |
| pubmed-article:20306568 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20306568 | pubmed:volume | 22 | lld:pubmed |
| pubmed-article:20306568 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20306568 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20306568 | pubmed:pagination | 494-9 | lld:pubmed |
| pubmed-article:20306568 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:20306568 | pubmed:meshHeading | pubmed-meshheading:20306568... | lld:pubmed |
| pubmed-article:20306568 | pubmed:meshHeading | pubmed-meshheading:20306568... | lld:pubmed |
| pubmed-article:20306568 | pubmed:meshHeading | pubmed-meshheading:20306568... | lld:pubmed |
| pubmed-article:20306568 | pubmed:meshHeading | pubmed-meshheading:20306568... | lld:pubmed |
| pubmed-article:20306568 | pubmed:meshHeading | pubmed-meshheading:20306568... | lld:pubmed |
| pubmed-article:20306568 | pubmed:meshHeading | pubmed-meshheading:20306568... | lld:pubmed |
| pubmed-article:20306568 | pubmed:meshHeading | pubmed-meshheading:20306568... | lld:pubmed |
| pubmed-article:20306568 | pubmed:meshHeading | pubmed-meshheading:20306568... | lld:pubmed |
| pubmed-article:20306568 | pubmed:meshHeading | pubmed-meshheading:20306568... | lld:pubmed |
| pubmed-article:20306568 | pubmed:meshHeading | pubmed-meshheading:20306568... | lld:pubmed |
| pubmed-article:20306568 | pubmed:meshHeading | pubmed-meshheading:20306568... | lld:pubmed |
| pubmed-article:20306568 | pubmed:meshHeading | pubmed-meshheading:20306568... | lld:pubmed |
| pubmed-article:20306568 | pubmed:meshHeading | pubmed-meshheading:20306568... | lld:pubmed |
| pubmed-article:20306568 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20306568 | pubmed:articleTitle | Subfulminant hepatitis B during treatment with adalimumab in a patient with rheumatoid arthritis and chronic hepatitis B. | lld:pubmed |
| pubmed-article:20306568 | pubmed:affiliation | Department of Gastroenterology and Hepatology, Ghent University Hospital, De Pintelaan 185, Ghent B-9000, Belgium. xavierverhelst@gmail.com | lld:pubmed |
| pubmed-article:20306568 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20306568 | pubmed:publicationType | Review | lld:pubmed |
| pubmed-article:20306568 | pubmed:publicationType | Case Reports | lld:pubmed |
